Display options
Cite
Liu F, Gong L, Qin W, et al. Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE. Diabetes Metab Syndr Obes. 2020;13:2701-2709doi: 10.2147/DMSO.S262479.
Liu, F., Gong, L., Qin, W., Cui, C., Chen, L., & Zhang, M. (2020). Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE. Diabetes, metabolic syndrome and obesity : targets and therapy, 132701-2709. https://doi.org/10.2147/DMSO.S262479
Liu, Fuqiang, et al. "Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 (2020): 2701-2709. doi: https://doi.org/10.2147/DMSO.S262479
Liu F, Gong L, Qin W, Cui C, Chen L, Zhang M. Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE. Diabetes Metab Syndr Obes. 2020 Jul 28;13:2701-2709. doi: 10.2147/DMSO.S262479. eCollection 2020. PMID: 32801816; PMCID: PMC7395686.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2020 Jul 28;13:2701-2709. doi: 10.2147/DMSO.S262479. eCollection 2020.

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE.

Diabetes, metabolic syndrome and obesity : targets and therapy

Fuqiang Liu, Lei Gong, Weidong Qin, Chen Cui, Li Chen, Mingxiang Zhang

Affiliations

  1. Department of Endocrinology, Qilu Hospital, Shandong University, Jinan 250012, People's Republic of China.
  2. Institute of Endocrine and Metabolic Diseases, Shandong University, Jinan 250012, People's Republic of China.
  3. Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine and Health, Jinan, People's Republic of China.
  4. Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Jinan, People's Republic of China.
  5. Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital, Shandong University, Jinan Shandong 250012, People's Republic of China.

PMID: 32801816 PMCID: PMC7395686 DOI: 10.2147/DMSO.S262479

Abstract

AIM: Glucagon-like peptide-1 (GLP1) is known to decrease glucagon release and may be beneficial for the reduction of elevated blood glucose. However, its role and mechanism of action in diabetes remain elusive. This study aimed to examine the function of GLP1 and analyze the mechanism of effect that GLP1exerts on inducible nitric oxide synthase (iNOS) in diabetic mice.

METHODS: A diabetes model was established in ApoE

RESULTS: GLP1 inhibited the expression of PARP1 and iNOS in islets, alleviated decrease in β cells, and suppressed cell apoptosis induced by the high-fat diet. Moreover, GLP1 recovered the decline in insulin sensitivity and glucose tolerance in ApoE

CONCLUSION: GLP1 significantly alleviated the decrease in β-cell numbers, suppressed β-cell apoptosis induced by the high-fat diet, inhibited the expression of iNOS, and alleviated inflammatory islet injury via inhibiting the COX2-NFκB pathway.

© 2020 Liu et al.

Keywords: GLP1; PARP1; islet function

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. J Diabetes Complications. 2015 Apr;29(3):445-50 - PubMed
  2. J Clin Invest. 1993 Nov;92(5):2313-22 - PubMed
  3. Chem Biol Drug Des. 2015 Dec;86(6):1482-90 - PubMed
  4. Cardiovasc Diabetol. 2004 Feb 04;3:1 - PubMed
  5. ILAR J. 2006;47(3):243-58 - PubMed
  6. J Biomed Sci. 2017 Sep 19;24(1):76 - PubMed
  7. Am J Cardiol. 2002 Oct 17;90(8A):55i-61i - PubMed
  8. Lipids. 2010 Apr;45(4):321-7 - PubMed
  9. J Biol Chem. 2006 Apr 7;281(14):9101-9 - PubMed
  10. N Engl J Med. 2010 Mar 25;362(12):1090-101 - PubMed
  11. Environ Pollut. 2018 May;236:948-952 - PubMed
  12. Open Cardiovasc Med J. 2011;5:153-63 - PubMed
  13. Mutat Res. 2012 Apr 1;732(1-2):9-15 - PubMed
  14. Surv Synth Pathol Res. 1985;4(2):110-25 - PubMed
  15. Cell Mol Life Sci. 2005 Apr;62(7-8):721-30 - PubMed
  16. J Clin Invest. 1996 May 1;97(9):2051-6 - PubMed
  17. Inflammation. 2001 Jun;25(3):157-63 - PubMed
  18. Bosn J Basic Med Sci. 2016 Aug 2;16(3):162-79 - PubMed
  19. J Biol Chem. 1992 Mar 5;267(7):4338-44 - PubMed
  20. Cell Tissue Res. 2005 Feb;319(2):221-30 - PubMed
  21. Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15 - PubMed
  22. J Clin Invest. 1994 Dec;94(6):2504-10 - PubMed
  23. Cardiovasc Pathol. 2011 Jul-Aug;20(4):195-203 - PubMed
  24. Endocrine. 2001 Nov;16(2):97-104 - PubMed
  25. J Intern Med. 1996 Feb;239(2):139-46 - PubMed
  26. Diabetes. 1991 Feb;40(2):166-80 - PubMed
  27. Electrophoresis. 2012 Feb;33(4):697-704 - PubMed
  28. Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E871-5 - PubMed
  29. Am J Physiol Cell Physiol. 2002 Jul;283(1):C296-304 - PubMed
  30. Endocrinology. 2003 Dec;144(12):5145-8 - PubMed
  31. Exp Ther Med. 2017 May;13(5):2558-2564 - PubMed
  32. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3456-3465 - PubMed
  33. Diabetes. 1976 Feb;25(2):136-51 - PubMed
  34. J Cardiovasc Pharmacol. 2016 Apr;67(4):283-9 - PubMed

Publication Types